Abstract
Angiotensin converting enzyme (ACE)-inhibitory drugs have been used as therapeutic tools in the clinical management of hypertension and associated cardiovascular disorders. Food-derived ACE-inhibitory peptides have lower potency than similar acting drugs but the peptides usually have no adverse side effects and there is virtually no risk of overdosing that is associated with drugs. This review summarizes several patents that have reported the development of technologies for the production of potent food protein-derived hydrolysates and peptides, which can be used to formulate antihypertensive functional foods and nutraceuticals. A common process to all the patents is the use of proteases to split large inactive proteins into smaller bioactive peptides. Ultrafiltration may be combined with liquid chromatography methods to separate the peptides according to size alone or a combination of size and charge density, respectively. Efficacy of the protein hydrolysates or peptide fractions is evaluated first in an in vitro system and may then be confirmed by measuring their hypotensive ability in an appropriate animal model such as the spontaneously hypertensive rats. Finally, protein hydrolysates or peptide fractions that have hypotensive ability may then be used to formulate foods, beverages or pills that can be taken as therapeutic tools against hypertension.
Keywords: Bioactive peptides, angiotensin converting enzyme, antihypertensive, food proteins, membrane ultrafiltration, protein hydrolysate, spontaneously hypertensive rats
Recent Patents on Biotechnology
Title: Technology for the Production and Utilization of Food Protein-Derived Antihypertensive Peptides: A Review
Volume: 1 Issue: 3
Author(s): Rotimi E. Aluko
Affiliation:
Keywords: Bioactive peptides, angiotensin converting enzyme, antihypertensive, food proteins, membrane ultrafiltration, protein hydrolysate, spontaneously hypertensive rats
Abstract: Angiotensin converting enzyme (ACE)-inhibitory drugs have been used as therapeutic tools in the clinical management of hypertension and associated cardiovascular disorders. Food-derived ACE-inhibitory peptides have lower potency than similar acting drugs but the peptides usually have no adverse side effects and there is virtually no risk of overdosing that is associated with drugs. This review summarizes several patents that have reported the development of technologies for the production of potent food protein-derived hydrolysates and peptides, which can be used to formulate antihypertensive functional foods and nutraceuticals. A common process to all the patents is the use of proteases to split large inactive proteins into smaller bioactive peptides. Ultrafiltration may be combined with liquid chromatography methods to separate the peptides according to size alone or a combination of size and charge density, respectively. Efficacy of the protein hydrolysates or peptide fractions is evaluated first in an in vitro system and may then be confirmed by measuring their hypotensive ability in an appropriate animal model such as the spontaneously hypertensive rats. Finally, protein hydrolysates or peptide fractions that have hypotensive ability may then be used to formulate foods, beverages or pills that can be taken as therapeutic tools against hypertension.
Export Options
About this article
Cite this article as:
Aluko E. Rotimi, Technology for the Production and Utilization of Food Protein-Derived Antihypertensive Peptides: A Review, Recent Patents on Biotechnology 2007; 1 (3) . https://dx.doi.org/10.2174/187220807782330129
DOI https://dx.doi.org/10.2174/187220807782330129 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design Contribution of MEK1/ERK1/2/iNOS Pathway to Oxidative Stress and Decreased Caspase-3 Activity in Endotoxemic Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity
Current Topics in Medicinal Chemistry A Review of the Nephrotoxicity of the Food Flavor Cinnamaldehyde
Current Bioactive Compounds Monoamine Oxidases: to Inhibit or Not to Inhibit
Mini-Reviews in Medicinal Chemistry Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Therapeutic Targeting of TRPV1 by Resiniferatoxin, from Preclinical Studies to Clinical Trials
Current Topics in Medicinal Chemistry Influence of Quaternary Conformation on the Biological Activities of the Asp49-phospholipases A2s from Snake Venoms
Protein & Peptide Letters Editorial [Hot Topic: Pain - Unmet Need and Emerging Targets & Therapies (Guest Editor: Sivaram Pillarisetti)]
CNS & Neurological Disorders - Drug Targets Revised Roberts Cytoprotection and Adaptive Cytoprotection and Stable Gastric Pentadecapeptide BPC 157. Possible Significance and Implications for Novel Mediator
Current Pharmaceutical Design Molecular and Cellular Mechanisms in the Pathophysiology of Severe Head Injury
Current Pharmaceutical Design New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Pathogenesis-Oriented Targets for Adjunctive Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Antibody Therapy of Acute and Chronic Leukemias
Current Pharmaceutical Biotechnology Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Regulatory Requirements for Collection, Administration and Transfusion of Blood and Blood Products
Applied Clinical Research, Clinical Trials and Regulatory Affairs PPARγ Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?
Current Hypertension Reviews Emergence in Pyrazolines: Synthetic and Biological Perspective
The Natural Products Journal